$PFE $LLY The FDA has approved  Pfizer Inc.'s  (PFE) BRAFTOVI in combination with Eli  Lilly 's (LLY) ERBITUX for the treatment of adult patients with metastatic colorectal cancer with a BRAFV600E mutation, as detected by an FDA-approved test, after prior therapy.